Squill - Ruxolitinib Interaction
Herbal: Squill
Also Known As: Urginea indica, Cebolla Albarrana, Charpentaire, European Squill, Indian Quills, Indian Squill, Jangli Pyaj, Jungli Plyaz, Mediterranean Squill, Oignon Marin, Red Squill, Scilla, Scille, Scille Maritime, Scille Officinale, Sea Onion, Sea Squill Bulb, Squille, Vanpalandu, Wh
Drug: Ruxolitinib
Brand names:
Jakafi, Opzelura
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Apr 13, 2024
Interaction Details
There were no interactions found between Ruxolitinib and Squill. This does not mean the potential for an interaction does not exist, however. There is often a lack of studies and data surrounding traditional medicine, especially concerning drug interactions, so it is important to always consult your provider before making any changes to your medication regimen.
Squill Overview
Squill is a type of bulbous perennial plant, also known as sea onion or sea squill, that is native to the Mediterranean region and the Black Sea coast. It has been used in traditional medicine and contains a substance known as scillaren A, which is believed to be responsible for its medicinal properties.
Squill has been used for a variety of purposes, including as an expectorant to relieve coughs, as a diuretic to increase urine production and as a 'cardiac tonic', to stimulate the heart and improve circulation. It has also been used topically for hair loss. However, it is important to note that squill contains cardiac glycosides that can be toxic and may cause serious side effects, such as an irregular heartbeat, low blood pressure, and death. It must be used cautiously.
Ruxolitinib Overview
-
Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people who were not able to be treated successfully with hydroxyurea. Ruxolitinib is also used to treat acute graft versus host disease (aGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that usually develops within the first months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with steroid medications. It is also used to treat chronic GVHD (cGVHD; a complication of HSCT that usually develops at least 3 months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with 1 or 2 other treatments. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.
Squill - More Interactions
Squill interacts with 156 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
| Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
| Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
| Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
| Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main herbal interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.
Ask A Pharmacist About Your Herbal Questions!
Dr. Brian Staiger, PharmD
In addition to being a clinical pharmacist specializing in pharmacotherapy, Dr. Brian Staiger is a registered herbalist through the American Herbalist Guild. He has combined his passion for pharmacy practice with the study of medical ethnobotany to improve patient care. Feel free to reach out about any of your herbal or medication questions!
Ask A Pharmacist